New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
06:11 EDTBCRXBioCryst reports Q4 EPS (22c), consensus (16c)
Reports Q4 revenue $4.1M, consensus $4.02M.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
10:00 EDTBCRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:26 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:45 EDTBCRXBioCryst upgraded to Buy on BCX7353 potential at BofA/Merrill
As previously reported, BofA/Merrill upgraded BioCryst to Buy from Neutral and increased its price target to $19 from $12. The firm raised the probability of BCX7353 approval to 40% from 25% given validation of the plasma kallikrein target by both 4161 and competitor product and now assign a $13/share value versus near zero previously. BofA/Merrill is now assigning a modest negative value for '4161 versus approximately $7/share previously.
06:00 EDTBCRXBioCryst upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use